Home | Contact Us | Site Map | Français
Enhancing the lives and outcomes
of Canadian individuals and families
affected by Barth syndrome."

References

  1. Barth, P G; Scholte, J A; Berden, J A; Van dKVM JM; Luyt-Houwen, IEM; Van't Veer-Korthof, ET; Van der Harten, JJ; Sobotka-Plojhar, MA. An X-linked mitochondrial disease affecting cardiac muscle, skeletal muscle and neutrophil leucocytes. J. Neurol. Sci. 62: 327-355, 1983.
  2. Orstavik, KH.; Orstavik, RE; Naumova, AK; D'Adamo, P; Gedeon, A; Bolhuis, PA; Barth, PG; Toniolo, D. X chromosome inactivation in carriers of Barth syndrome. Am. J. Hum. Genet. 63: 1457-1463, 1998.
  3. Kelley, RI; Cheatham, JP; Clark, BJ; Nigro, MA; Powell, BR; Sherwood, GW; Sladky, JT; Swisher, WP. X-linked dilated cardiomyopathy with neutropenia, growth retardation, and 3-methylglutaconic aciduria. J. Pediat. 119: 738-747, 1991.
  4. Christodoulou, J.; McInnes, RR.; Jay, V; Wilson, G; Becker, LE; Lehotay, DC; Platt, BA; Bridge, PJ; Robinson, BH; Clarke, JT. Barth syndrome: clinical observations and genetic linkage studies. Am. J. Med. Genet. 50: 255-264, 1994.
  5. Barth PG; Wanders RJ; Vreken P; Janssen EA; Lam J; Baas F. X-linked cardioskeletal myopathy and neutropenia (Barth syndrome) (MIM 302060)J Inherit Metab Dis 22:555 – 567, 1999.
  6. Bleyl SB, Mumford BR, Brown-Harrison MC, Pagotto LT, Carey JC, Pysher TJ, et al. Xq28-linked noncompaction of the left ventricular myocardium: prenatal diagnosis and pathologic analysis of affected individuals. Am J Med Genet ;72(3):257-65, 1997.
  7. Cardonick EH, Kuhlman K, Ganz E, Pagotto LT. Prenatal clinical expression of 3-methylglutaconic aciduria: Barth syndrome. Prenat Diagn ;17(10):983-8, 1997.
  8. Bleyl SB, Mumford BR, Thompson V, Carey JC, Pysher TJ, Chin TK, et al. Neonatal, lethal noncompaction of the left ventricular myocardium is allelic with Barth syndrome. Am J Hum Genet; 61(4):868-72,1997.
  9. Ichida F, Tsubata S, Bowles KR, Haneda N, Uese K, Miyawaki T, et al. Novel gene mutations in patients with left ventricular noncompaction or Barth syndrome. Circulation; 103(9):1256-63, 2001.
  10. Kelley, RI. Quantification of 3-methylglutaconic acid in urine, plasma, and amniotic fluid by isotope-dilution gas chromatography/mass spectrometry. Clin Chim Acta 220(2): 157 -64, 1993.
  11. Gibson, KM: Elpeleg, ON; Kakobs, C; Costeff, H; Kelley, RI. Multiple syndromes of 3-methylglutaconic aciduria. Pedatr Neurol 9 (2): 120 – 3, 1993.
  12. Mazzocco, MM; Kelley, RI. Preliminary evidence for cognitive phenotype in Barth syndrome. Am J Med Genet 102: 372 – 378, 2001.
  13. Schlame, M.; Towbin, JA; Heerdt, PM; Jehle, R; DiMauro, S; Blanck, TJJ. Deficiency of tetralinoleoyl-cardiolipin in Barth syndrome. Ann. Neurol. 51: 634-637, 2002.
  14. Vreken, P; Valianpour, F; Nijtmans, LG; Grivell, LA; Plecko, B; Wanders, RJA; Barth, PG. Defective remodeling of cardiolipin and phosphatidylglycerol in Barth syndrome. Biochem. Biophys. Res. Commun. 279: 378-382, 2000.

Privacy and Disclaimer

Barth Syndrome Foundation of Canada does not endorse any drugs, tests, or treatments that we may report.

This website is for informational purposes, always check with your physician before adopting any medical treatment.

Registered Charity Number:
86102 2002 RR0001

© Barth Syndrome Foundation. All rights reserved.
Web Design by Pixelera